AMNEAL PHARMACEUTICALS, INC. (AMRX)

Import this data to Google Sheets with:

=jivedata("AMRX","financials")

Full statements spill as a table. For one cell: =jivedata("AMRX","Revenue") or =jivedata("AMRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

AMNEAL PHARMACEUTICALS, INC.

AMRX • CIK 0001723128

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,393,607	$2,793,957	$3,018,760	$3,117,548
Cost of Goods and Services Sold	$1,573,042	$1,773,519	$1,905,452	$1,891,763
Gross Profit	$820,565	$1,020,438	$1,113,308	$1,225,785
Selling, General and Administrative Expense	$429,675	$476,436	$526,827	$571,855
Research and Development Expense	$163,950	$190,714	$186,175	$175,571
Asset Impairment Charges	$30,800	$0	$0	$0
Restructuring Charges	$1,749	$2,355	$4,208	$3,817
Gain (Loss) Related to Litigation Settlement	$-1,824	$-96,692	$390	$-8,751
Other Operating Income (Expense), Net	$1,138	$0	$5,240	$8,357
Operating Income (Loss)	$204,374	$249,326	$394,096	$453,918
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-40,270	$-55,013	$139,209	$201,178
Income Tax Expense (Benefit)	$8,452	$18,863	$11,276	$-14,141
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-48,722	$-73,876	$127,933	$215,319
Net Income (Loss) Attributable to Noncontrolling Interest	$35,271	$43,010	$55,876	$57,956
Net Income (Loss) Attributable to Parent	$-79,265	—	$72,057	$157,363
Interest Income (Expense), Nonoperating, Net	$-210,629	$-258,595	$-241,091	$-227,455
Foreign Currency Transaction Gain (Loss), before Tax	$1,671	$-6,846	$7,635	$-14,618
Gain (Loss) on Extinguishment of Debt	$-40,805	$0	$-31,365	$-34,875
Other Nonoperating Income (Expense)	$5,119	$11,782	$16,522	$15,795
Nonoperating Income (Expense)	$-244,644	$-304,339	$-254,887	$-252,740
Weighted Average Number of Shares Outstanding, Basic	176,136,000	308,978,000	313,367,000	318,583,000
Weighted Average Number of Shares Outstanding, Diluted	176,136,000	308,978,000	324,805,000	330,161,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$447,574	$424,908	$442,950	$456,877
Goodwill	$598,629	$597,436	$595,470	$593,499
Intangible Assets, Net (Excluding Goodwill)	$890,423	$732,377	$563,498	$587,830
Operating Lease, Right-of-Use Asset	$43,283	$42,352	$54,048	$54,048
Other Assets, Noncurrent	$55,517	$60,133	$57,805	$80,669
Assets	$3,472,569	$3,501,445	$3,678,280	$3,776,348
Long-term Debt, Excluding Current Maturities	$2,386,004	$2,161,790	$2,565,115	$2,564,335
Estimated Litigation Liability, Noncurrent	$316	$85,479	$71,819	$70,830
Liabilities, Noncurrent	$2,564,670	$2,416,212	$2,790,684	$2,776,181
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests	$41,293	$64,974	$77,292	$83,956
Cash and Cash Equivalents, at Carrying Value	$91,542	$110,552	$282,029	$127,637
Restricted Cash and Cash Equivalents, Current	$7,565	$7,868	$28,842	$8,643
Inventory, Net	$581,384	$612,454	$606,302	$677,954
Prepaid Expense and Other Assets, Current	$82,685	$80,717	$98,395	$112,011
Assets, Current	$1,377,863	$1,587,806	$1,911,181	$1,947,029
Estimated Litigation Liability, Current	$76,988	$31,755	$43,256	$18,488
Line of Credit, Current	$179,000	$100,000	$0	$100,000
Long-term Debt, Current Maturities	$34,125	$224,213	$6,761	$5,961
Liabilities, Current	$846,595	$1,129,771	$881,633	$883,187
Preferred Stock, Value, Issued	$0	$0	$0	$0
Additional Paid in Capital	$539,240	$560,206	$571,794	$545,584
Retained Earnings (Accumulated Deficit)	$-490,176	$-607,062	$-535,005	$-415,087
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-32,349	$-65,510	$-110,729	$-100,666
Stockholders' Equity Attributable to Parent	$19,781	$-109,267	$-70,794	$33,024
Stockholders' Equity Attributable to Noncontrolling Interest	$230	$-245	$-535	$0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$20,011	$-109,512	$-71,329	$33,024
Preferred Stock, Shares Authorized	2,000,000	2,000,000	2,000,000	2,000,000
Preferred Stock, Shares Issued	0	0	0	0
Operating Lease, Liability	$48,914	$47,036	$58,801	$58,801
Finance Lease, Liability	$61,033	$60,100	$58,369	$58,369
Interest Rate Cash Flow Hedge Asset at Fair Value	$37,089	$35,921	—	$5,168

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-48,722	$-73,876	$127,933	$215,319
Net Cash Provided by (Used in) Operating Activities	$345,577	$295,099	$339,992	$200,778
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$65	$-999	$-1,680	$-2,090
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$63,880	$19,313	$194,519	$55,947
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$99,107	$118,420	$312,939	$448,953
Cash and Cash Equivalents, at Carrying Value	$91,542	$110,552	$282,029	$420,498
Restricted Cash and Cash Equivalents, Current	$7,565	$7,868	$28,842	$26,433
Restricted Cash and Cash Equivalents, Noncurrent	—	—	$2,068	$2,022
Payments to Acquire Property, Plant, and Equipment	$43,216	$51,924	$70,063	$72,943
Foreign Currency Transaction Gain (Loss), Unrealized	$768	$-7,191	$7,453	$-14,855
Payments to Acquire Intangible Assets	$22,388	$14,650	$15,514	$95,414
Amortization of Debt Issuance Costs and Discounts	$8,182	$29,097	$22,431	$16,699
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	—	—	$-1,229	$-12,893
Gain (Loss) on Extinguishment of Debt	$-40,805	$0	$-31,365	$-34,875
Proceeds from Sales of Business, Affiliate and Productive Assets	—	$11,994	$0	$0
Impairment of Intangible Assets (Excluding Goodwill)	$66,932	$920	$22,784	$22,784
Net Cash Provided by (Used in) Investing Activities	$-69,189	$-62,996	$-112,263	$-212,370
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$-14,497	$-930	$0	$0
Share-based Payment Arrangement, Noncash Expense	$26,822	$27,768	$31,953	$35,629
Inventory Write-down	$74,686	$96,558	$85,962	$92,487
Other Noncash Income (Expense)	$-9,923	$-2,453	$-4,732	$-5,564
Increase (Decrease) in Accounts Receivable	$-126,289	$162,637	$120,566	$213,716
Proceeds from Issuance of Debt	$217,732	$0	$2,694,750	$2,829,423
Increase (Decrease) in Inventories	$126,182	$130,530	$87,026	$175,137
Increase (Decrease) in Prepaid Expense and Other Assets	$-37,814	$959	$19,163	$33,298
Payment for Debt Extinguishment or Debt Prepayment Cost	—	$71	$74,973	$74,973
Increase (Decrease) in Due from Related Parties	$490	$-482	$13	$-1,120
Proceeds from Lines of Credit	$219,000	$48,000	$218,000	$100,000
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$-94,446	$235,135	$21,321	$30,407
Proceeds from Stock Options Exercised	$451	$1,154	$1,960	$1,286
Increase (Decrease) in Due to Related Parties	$9,829	$54,441	$931	$-53,994
Payment, Tax Withholding, Share-based Payment Arrangement	$2,378	$7,952	$22,278	$44,931
Repayments of Related Party Debt	$0	$44,200	$0	$0
Net Cash Provided by (Used in) Financing Activities	$-212,573	$-211,791	$-31,530	$69,629
Interest Paid, Excluding Capitalized Interest, Operating Activities	$192,806	$263,518	$197,848	$176,950
Income Taxes Paid, Net	$-2,496	$15,220	$21,327	$9,076
Notes Issued	—	—	$476	$-26

Jive Data

Google Sheets add-onSheets Account

Import this data to Google Sheets with:

=jivedata("AMRX","financials")

Full statements spill as a table. For one cell: =jivedata("AMRX","Revenue") or =jivedata("AMRX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

AMNEAL PHARMACEUTICALS, INC.

AMRX • CIK 0001723128

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,393,607	$2,793,957	$3,018,760	$3,117,548
Cost of Goods and Services Sold	$1,573,042	$1,773,519	$1,905,452	$1,891,763
Gross Profit	$820,565	$1,020,438	$1,113,308	$1,225,785
Selling, General and Administrative Expense	$429,675	$476,436	$526,827	$571,855
Research and Development Expense	$163,950	$190,714	$186,175	$175,571
Asset Impairment Charges	$30,800	$0	$0	$0
Restructuring Charges	$1,749	$2,355	$4,208	$3,817
Gain (Loss) Related to Litigation Settlement	$-1,824	$-96,692	$390	$-8,751
Other Operating Income (Expense), Net	$1,138	$0	$5,240	$8,357
Operating Income (Loss)	$204,374	$249,326	$394,096	$453,918
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-40,270	$-55,013	$139,209	$201,178
Income Tax Expense (Benefit)	$8,452	$18,863	$11,276	$-14,141
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-48,722	$-73,876	$127,933	$215,319
Net Income (Loss) Attributable to Noncontrolling Interest	$35,271	$43,010	$55,876	$57,956
Net Income (Loss) Attributable to Parent	$-79,265	—	$72,057	$157,363
Interest Income (Expense), Nonoperating, Net	$-210,629	$-258,595	$-241,091	$-227,455
Foreign Currency Transaction Gain (Loss), before Tax	$1,671	$-6,846	$7,635	$-14,618
Gain (Loss) on Extinguishment of Debt	$-40,805	$0	$-31,365	$-34,875
Other Nonoperating Income (Expense)	$5,119	$11,782	$16,522	$15,795
Nonoperating Income (Expense)	$-244,644	$-304,339	$-254,887	$-252,740
Weighted Average Number of Shares Outstanding, Basic	176,136,000	308,978,000	313,367,000	318,583,000
Weighted Average Number of Shares Outstanding, Diluted	176,136,000	308,978,000	324,805,000	330,161,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$447,574	$424,908	$442,950	$456,877
Goodwill	$598,629	$597,436	$595,470	$593,499
Intangible Assets, Net (Excluding Goodwill)	$890,423	$732,377	$563,498	$587,830
Operating Lease, Right-of-Use Asset	$43,283	$42,352	$54,048	$54,048
Other Assets, Noncurrent	$55,517	$60,133	$57,805	$80,669
Assets	$3,472,569	$3,501,445	$3,678,280	$3,776,348
Long-term Debt, Excluding Current Maturities	$2,386,004	$2,161,790	$2,565,115	$2,564,335
Estimated Litigation Liability, Noncurrent	$316	$85,479	$71,819	$70,830
Liabilities, Noncurrent	$2,564,670	$2,416,212	$2,790,684	$2,776,181
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests	$41,293	$64,974	$77,292	$83,956
Cash and Cash Equivalents, at Carrying Value	$91,542	$110,552	$282,029	$127,637
Restricted Cash and Cash Equivalents, Current	$7,565	$7,868	$28,842	$8,643
Inventory, Net	$581,384	$612,454	$606,302	$677,954
Prepaid Expense and Other Assets, Current	$82,685	$80,717	$98,395	$112,011
Assets, Current	$1,377,863	$1,587,806	$1,911,181	$1,947,029
Estimated Litigation Liability, Current	$76,988	$31,755	$43,256	$18,488
Line of Credit, Current	$179,000	$100,000	$0	$100,000
Long-term Debt, Current Maturities	$34,125	$224,213	$6,761	$5,961
Liabilities, Current	$846,595	$1,129,771	$881,633	$883,187
Preferred Stock, Value, Issued	$0	$0	$0	$0
Additional Paid in Capital	$539,240	$560,206	$571,794	$545,584
Retained Earnings (Accumulated Deficit)	$-490,176	$-607,062	$-535,005	$-415,087
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-32,349	$-65,510	$-110,729	$-100,666
Stockholders' Equity Attributable to Parent	$19,781	$-109,267	$-70,794	$33,024
Stockholders' Equity Attributable to Noncontrolling Interest	$230	$-245	$-535	$0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$20,011	$-109,512	$-71,329	$33,024
Preferred Stock, Shares Authorized	2,000,000	2,000,000	2,000,000	2,000,000
Preferred Stock, Shares Issued	0	0	0	0
Operating Lease, Liability	$48,914	$47,036	$58,801	$58,801
Finance Lease, Liability	$61,033	$60,100	$58,369	$58,369
Interest Rate Cash Flow Hedge Asset at Fair Value	$37,089	$35,921	—	$5,168

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-48,722	$-73,876	$127,933	$215,319
Net Cash Provided by (Used in) Operating Activities	$345,577	$295,099	$339,992	$200,778
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$65	$-999	$-1,680	$-2,090
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$63,880	$19,313	$194,519	$55,947
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$99,107	$118,420	$312,939	$448,953
Cash and Cash Equivalents, at Carrying Value	$91,542	$110,552	$282,029	$420,498
Restricted Cash and Cash Equivalents, Current	$7,565	$7,868	$28,842	$26,433
Restricted Cash and Cash Equivalents, Noncurrent	—	—	$2,068	$2,022
Payments to Acquire Property, Plant, and Equipment	$43,216	$51,924	$70,063	$72,943
Foreign Currency Transaction Gain (Loss), Unrealized	$768	$-7,191	$7,453	$-14,855
Payments to Acquire Intangible Assets	$22,388	$14,650	$15,514	$95,414
Amortization of Debt Issuance Costs and Discounts	$8,182	$29,097	$22,431	$16,699
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	—	—	$-1,229	$-12,893
Gain (Loss) on Extinguishment of Debt	$-40,805	$0	$-31,365	$-34,875
Proceeds from Sales of Business, Affiliate and Productive Assets	—	$11,994	$0	$0
Impairment of Intangible Assets (Excluding Goodwill)	$66,932	$920	$22,784	$22,784
Net Cash Provided by (Used in) Investing Activities	$-69,189	$-62,996	$-112,263	$-212,370
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$-14,497	$-930	$0	$0
Share-based Payment Arrangement, Noncash Expense	$26,822	$27,768	$31,953	$35,629
Inventory Write-down	$74,686	$96,558	$85,962	$92,487
Other Noncash Income (Expense)	$-9,923	$-2,453	$-4,732	$-5,564
Increase (Decrease) in Accounts Receivable	$-126,289	$162,637	$120,566	$213,716
Proceeds from Issuance of Debt	$217,732	$0	$2,694,750	$2,829,423
Increase (Decrease) in Inventories	$126,182	$130,530	$87,026	$175,137
Increase (Decrease) in Prepaid Expense and Other Assets	$-37,814	$959	$19,163	$33,298
Payment for Debt Extinguishment or Debt Prepayment Cost	—	$71	$74,973	$74,973
Increase (Decrease) in Due from Related Parties	$490	$-482	$13	$-1,120
Proceeds from Lines of Credit	$219,000	$48,000	$218,000	$100,000
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$-94,446	$235,135	$21,321	$30,407
Proceeds from Stock Options Exercised	$451	$1,154	$1,960	$1,286
Increase (Decrease) in Due to Related Parties	$9,829	$54,441	$931	$-53,994
Payment, Tax Withholding, Share-based Payment Arrangement	$2,378	$7,952	$22,278	$44,931
Repayments of Related Party Debt	$0	$44,200	$0	$0
Net Cash Provided by (Used in) Financing Activities	$-212,573	$-211,791	$-31,530	$69,629
Interest Paid, Excluding Capitalized Interest, Operating Activities	$192,806	$263,518	$197,848	$176,950
Income Taxes Paid, Net	$-2,496	$15,220	$21,327	$9,076
Notes Issued	—	—	$476	$-26

AMNEAL PHARMACEUTICALS, INC.

Consolidated Statementsof Operations

Consolidated Balance Sheets

Consolidated Statementsof Cash Flows

AMNEAL PHARMACEUTICALS, INC.

Consolidated Statementsof Operations

Consolidated Balance Sheets

Consolidated Statementsof Cash Flows